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A REVIEW OF THERAPEUTICS TARGETING EXCITOTOXICITY 
IN AMYOTROPHIC LATERAL SCLEROSIS 
 
JOSHUA CHANG 
ABSTRACT 
 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative 
disease that affects between 14,000 to 15,000 Americans. The upper and lower 
motor neurons degenerate, which eventually causes muscle paralysis, atrophy, 
and ultimately death from respiratory failure. It has a high treatment cost as well 
as a high toll on the patient and their families and friends. Currently, there are 
only two drugs approved by the FDA for the treatment of ALS: riluzole and 
edaravone. Research is constantly being conducted to understand and develop 
further treatment modalities, however, many drugs have failed to demonstrate 
significant improvement in phase III trials. One of the pathophysiology that these 
drugs, including riluzole, target is excitotoxicity of the motor neurons.  
 
This review will briefly expand upon the different trials that were conducted 
targeting the excitotoxicity pathway. Although they may have not been successful 
in prolonging survival in ALS patients, we can learn from these studies and build 
upon them. 
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INTRODUCTION 
 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative 
disease identified by the degeneration of upper and lower motor neurons that 
innervate skeletal muscle. This degeneration causes muscle paralysis, atrophy, 
and ultimately death from respiratory failure, usually within three to five years 
from diagnosis (Gordon, 2013). Only two drugs are currently approved by the 
United States Food and Drug Association (FDA) for the treatment of ALS: riluzole 
and edaravone  (Ceccanti et al., 2018; Kuźma-Kozakiewicz, 2018). They have 
shown modest effects in prolonging life, but there is currently no cure or effective 
treatment to halt or reverse the progression of the disease. In 2016, the Center of 
Disease Control and Prevention estimated ALS affects between 14,000 to 15,000 
Americans; a majority of these cases are considered sporadic (90% or more) 
while the remaining cases are familial (“Amyotrophic Lateral Sclerosis (ALS) Fact 
Sheet | National Institute of Neurological Disorders and Stroke,” 2018). With high 
treatment costs of around $63,693 per patient for no effective therapy, it is a 
difficult disease for both patient and family. The cost of ALS treatment is 
estimated to be over $1 billion in the United States alone (Larkindale et al., 
2014). 
 
However, as our understanding of the diseases deepens, new ALS 
therapies are emerging and are under investigation. There are currently three 
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major hypothesized pathophysiologic mechanisms for ALS that are the targets 
for therapies: excitotoxicity, protein aggregation, and oxidative stress (Gordon, 
2013). This review will focus on therapies targeting excitoxicity in ALS. 
 
Normally, excitatory input into motor neuron dendrites involves synaptic 
signaling with the amino acid glutamate. Glutamate opens the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and, with 
sustained depolarization, the N-methyl-D-aspartate (NMDA) receptor. Synaptic 
glutamate is quickly cleared by neighboring astrocytes that express the excitatory 
amino acid transporter 2 (EAAT2). Surrounding interneurons and Renshaw cells 
also provide inhibitory inputs onto motor neurons to modulate excitatory signals 
and mitigate the build-up of glutamate (Blasco, Mavel, Corcia, & Gordon, 2014) 
 
However, in familial ALS (fALS) and spontaneous ALS (sALS) patients, it 
has been shown that EAAT2 levels are decreased in spinal cord samples. The 
abnormal accumulation of glutamate and derangement of inhibitory inputs are 
thought to permit the abnormal influx of calcium into motor neurons. Furthermore, 
motor neurons in ALS patients have an intrinsically diminished capacity to buffer 
the increased calcium currents generated by excitotoxic levels of synaptic 
glutamate – demonstrating intrinsic hyperexcitability. These changes lead to the 
generation of reactive oxygen species and subsequent apoptotic cascades. 
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Ultimately producing the disease state (Blasco et al., 2014; Van Den Bosch, Van 
Damme, Bogaert, & Robberecht, 2006) 
 
Although this hypothesis has been demonstrated in the lab, major drug 
trials targeting excitotoxicity has had largely no effect in phase III trials. Riluzole 
is the only drug currently approved for ALS treatment for excitotoxicity by the 
U.S. FDA back in 1995. Riluzole possesses an anti-glutamatergic property that 
may reduce excitotoxicity in ALS. It acts by three parallel mechanisms: by 
inhibiting glutamate release, by blocking NMDA receptors, and by stabilizing an 
inactivated state of voltage-gated sodium channels (Bezprozvanny, 2009). 
However, it only has a modest effect on the disease course, extending the 
median overall survival by approximately three months (Ceccanti et al., 2018). 
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Figure 1. Excitotoxicity model in ALS. Demonstrates the the cascade initiated by 
glutamate binding to the AMPA and NMDA receptors. Glutamate is taken up by 
astrocytes expressing the EAAT2 receptors. Antiglutamate agent riluzole acts by 
inhibiting glutamate release, blocking NMDA receptors, and stabilizing an 
inactivated state of voltage-gated sodium channels. Figure taken from 
Bezprozvanny, 2009 (Bezprozvanny, 2009). 
 
Recently approved in May 2017, the other U.S. FDA approved drug, 
Edaravone, targets the oxidative stress pathophysiology of ALS. The mechanism 
of action for the treatment of ALS is unclear, however, it is hypothesized to be 
based on radical scavenging properties. Edaravone neutralizes free oxygen 
species by adding a spare electron inside the cytoplasm and diffuses through the 
cell membrane. Phase III trials have demonstrated decreased disease 
progression in a select pool of ALS patients: early-stage ALS with no respiratory 
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involvement and indications for gastrostomy. Although Edaravone is not a 
permanent treatment, it has provided a new treatment strategy in the ALS field in 
22 years (Kuźma-Kozakiewicz, 2018). 
 
Still, further research and therapies are being investigated. This review will 
compare preliminary trials and novel therapeutics that target the excitotoxicity 
pathway of ALS. Past major trials have included Gabapentin and Ceftriaxone and 
current trials include Mexiletine, Dextromethorphan, and Retigabine. 
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SPECIFIC AIMS OR OBJECTIVES 
 
The objective of this study is to review the excitotoxicity pathology of ALS 
and compare the preliminary trials and novel therapeutics that target this 
pathway. This comprehensive review will provide a current understanding of the 
various therapeutic pipelines tackling the pathology of ALS. 
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PUBLISHED STUDIES 
 
RILUZOLE 
  As stated above, riluzole is the only U.S. FDA approved drug which 
targets excitoxocity in ALS. From June 1990 through March 1992, 155 ALS 
patients (32 with bulbar-onset disease and 123 with limb-onset disease) were 
enrolled to evaluate the efficacy and safety of riluzole (Bensimon, Lacomblez, 
Meininger, & Group, 2010). Patients were of 20 – 75 years of age with clinical 
status consistent with probable or definite ALS. The trial excluded patients with 
signs of conduction blocks of motor and/or sensory nerves, paraproteinemia, 
substantial lesions, or signs of dementia. They also excluded patients with more 
than five years since onset of their first symptoms, other life-threatening 
diseases, forced vital capacity of 60% of expected value, tracheostomy, hepatic 
or renal dysfunction, or if they were pregnant (Bensimon et al., 2010). 
 
The study was structured as a double-blind, placebo-controlled trial where 
patients were either given riluzole 50 mg bid or placebo 50 mg bid to be taken 
orally, morning and evening, before meals. The trial continued under double-blind 
conditions for 12 months, then the patients receiving placebo were switched to 
riluzole for 9 months. Patients were scheduled for examination every 2 months 
and the primary efficacy outcomes were defined as survival and changes in 
functional status after 12 months of treatment. The secondary efficacy outcomes 
were defined as changes in muscle strength, respiratory function, scores on the 
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Clinical Global Impression of Change Scale, and the patient’s subjective 
evaluations of fasciculations, cramps, stiffness, and tiredness, expressed on four 
100-mm visual-analogue scales (Bensimon et al., 2010). 
 
After 12 months of treatment, there was a statistically significant difference 
in survival between the two study groups. 45 of the 78 patients in the placebo 
group remained alive (58%), while 57 of the 77 in the riluzole group (74%) (p = 
0.014). A post-hoc analysis that excluded 24 patients, who did not meet the entry 
criteria, changed the percentages of surviving patients to 60% and 71% for the 
placebo and riluzole groups, respectively. Due to the reduced statistical power, 
the survival difference was no longer significant (p = 0.11) (Bensimon et al., 
2010). 
 
After 21 months (placebo group was switched to riluzole after 12 months), 
21 of 78 patients (37%) and 38 of 77 patients (49%) remained alive in the 
placebo and riluzole groups, respectively (p = 0.046). The median survival was 
449 days on the placebo and 532 days on riluzole. This study demonstrated 
riluzole therapy to reduce mortality by 38.6% at 12 months and by 19.4% at 21 
months, which were both clinically important and statistically significant 
(Bensimon et al., 2010). 
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Figure 2. Kaplan-Meier Plots of survival in ALS patients who were given placebo 
or riluzole. In the overall population panel, the curves of the two groups differed 
significantly at 12 months (p = 0.014) and at 21 months (p = 0.046). In the bulbar-
onset disease panel, the curves differed significantly at 12 months (p = 0.014) and 
at 21 months (p = 0.013). In the limb-onset disease panel, the curves did not differ 
significantly at either time points. Figure taken from Bensimon et al., 2010 
(Bensimon et al., 2010). 
 
The study also demonstrated that the effect of riluzole treatment was 
greater in patients with bulbar-onset disease than in those with limb-onset 
disease (Figure 2). Of the patients with bulbar-onset disease, 6 of 17 patients in 
the placebo group (35%) remained alive after 12 months, while 11 of 15 patients 
in the riluzole group (73%) remained alive (P = 0.014). 3 of 17 patients (18%) and 
8 of 15 patients (53%) (p = 0.013) remained alive after 21 months in the placebo 
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and riluzole groups, respectively. The median survival was 239 days in the 
placebo group compared to 476 days in the riluzole group (Bensimon et al., 
2010). 
 
Of the patients with limb-onset disease, 39 of 61 patients (64%) and 46 of 
62 patients (74%) remained alive after 12 months in the placebo and riluzole 
groups, respectively. This was not statistically significant (p = 0.17). By the end of 
21 months, 26 of 61 patients (43%) in the placebo group and 30 of 62 patients 
(48%) in the riluzole group remained alive (p = 0.355). There was no difference in 
median survival between the two groups (523 vs. 531 days for placebo and 
riluzole, respectively) (Bensimon et al., 2010).  
 
After adjustment for significant prognostic variables, such as age, duration 
of disease, forced vital capacity, bulbar-function score, the tiredness score, and 
stiffness scores, the survival rates between the two groups were only significant 
at 12 months (p = 0.005). it was nearly significant at 123 months (p = 0.058) 
(Bensimon et al., 2010). 
 
During the 12 month follow-up, a functional evaluation was conducted 
testing the limb function, bulbar function, and muscle strength (Figure 3). For 
each functional score, the rate of deterioration was slower in the riluzole 
treatment group than in the placebo group. However, only the muscle strength 
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score was statistically significant (p = 0.028). Only the effect of treatment 
assignment was statistically significant, regardless of the site of disease onset 
(Bensimon et al., 2010). 
 
Figure 3. Mean Annual Rates of Deterioration in ALS Patients given Placebo or 
Riluzole Treatments. Demonstrates rates of deterioration in limb function, bulbar 
function, and muscle strength (numbers inside the bars). 75 patients were studied 
in each group (Bensimon et al., 2010). 
 
Throughout the duration of the study, 19 patients in the riluzole group 
discontinued the treatment due to adverse experiences. Clinically important 
adverse drug reactions included worsening of asthenia; worsening of spasticity; 
increases in alanine aminotransferase and/or aspartate aminotransferase; and 
increase in blood pressure. Overall, 27 patients in the riluzole group and 17 
patients in the placebo groups discontinued treatment during the study 
(Bensimon et al., 2010). 
	12 
 
Through this study, riluzole was demonstrated to have a significant effect 
on the rates of survival and muscular deterioration in patients with ALS. The 
therapeutic effects of riluzole seemed to be stronger in the first 12 months than 
afterwards and a more significant effect on patients with ALS of bulbar onset than 
limb onset. The therapeutic effects also seem to outweigh the adverse drug 
reactions, which mainly affect the patient’s quality of life (Bensimon et al., 2010). 
 
GABAPENTIN 
Since riluzole was approved by the U.S. FDA in 1995, there have been 
many studies to further develop treatment options with no success until 
edaravone in 2017. One such unsuccessful treatment option that targeted 
excitotoxicity was gabapentin. Gabapentin was approved by the FDA in 1993 as 
an adjuvant medication to control partial seizures in adults (“Neurontin FDA 
Approved Labeling Text,” n.d.). Studies had suggested glutamate excitotoxicity 
may be reduced by gabapentin. Although the mechanism is unclear, gabapentin 
could reduce the pool of releasable glutamate. Gabapentin demonstrated a 
neuroprotective effect in tissue culture models of glutamate excitotoxicity and 
prolonged survival in mSOD1 mice, a transgenic mouse model of motor neuron 
disease (Miller et al., 1996). 
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A phase II trial of designed to evaluate the efficacy of gabapentin in 
slowing the rate of decline in muscle strength of ALS patients. The study chose 
152 patients between the ages of 21 and 85 with a diagnosis of ALS with 
symptoms for no more than 3 yrs prior to the study. The study was structured as 
a double-blind, placebo-controlled trial where patients were given oral gabapentin 
800 mg or placebo t.i.d. for 6 months. The patients were followed up monthly for 
the 6 months as well as one month after the last dose of the study. At each visit, 
physical examinations, body weight, and blood and urine samples were 
collected. The primary efficacy outcomes of the study were based on maximum 
voluntary isometric contractions (MVC) strength of eight arm muscle groups 
(bilateral shoulder and elbow flexion and extension). The secondary efficacy 
outcomes were the rates of decline of forced vital capacity (FVC) and arm 
strength score slope for patients who had completed all 6 monthly visits (Miller et 
al., 1996). 
 
At the end of the trial, an analysis of the arm megascores (all 8 arm 
muscle groups) demonstrated a trend towards a slower rate of decline in ALS 
patients taking gabapentin compared to those taking the placebo (Figure 4). The 
analysis of the arm megascores for patients who completed all seven visits 
showed a slope of -0.0044/day for placebo and -0.0033/day for gabapentin (p = 
0.13). However, this was not statistically significant. The decline in FVC was not 
statistically significant as well: -0.068%/day for placebo and -0.090%/day for 
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gabapentin (p = 0.35). In fact, patients taking gabapentin had a slightly greater 
rate of decline in FVC than patients taking the placebo. The reasons for this is 
unclear (Miller et al., 1996). 
 
 
Figure 4. Arm Megascore Medians by Visit for Patients who completed all 
seven visits. Open circles represent the placebo medians; closed circles 
represent the gabapentin medians. The sloping lines represents the median 
slopes (Miller et al., 1996) 
 
Although gabapentin did demonstrate a trend towards slowing the decline 
of arm megascores in ALS patients, it only showed a modest difference and did 
not achieve statistical significance. It also did not have any significant effect on 
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FVC. However, it was well-tolerated by patients, who mainly experienced light-
headedness, drowsiness, fatigue, and limb swelling if they experienced adverse 
effects at all (Table 1). No clinically significant safety concerns were observed in 
this study.  (Miller et al., 1996) 
 
Table 1. Frequency of Adverse Effects (Miller et al., 1996)* 
 
CEFTRIAXONE 
Ceftriaxone was a continuous three-phase trial drug, that was approved by 
the FDA as a beta-lactam antibiotic that significantly increases EAAT2 activity 
and GLT-1 expression in rodent brains (Rothstein et al., 2005). Further studies 
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have shown ceftriaxone to increase EAAT2 promoter activity and protect motor 
neurons from excitotoxicity in human astrocyte cultures as well as reduce 
glutamate excitotoxicity in animal models of spinal muscular atrophy, 
Huntington’s disease, ischemia, and multiple sclerosis. In primary human fetal 
astrocytes (PHFA), Ceftriaxone was shown to elevate EAAT2 transcription 
through the nuclear factor-	κB (NF-κB) signaling pathway. It was also 
demonstrated that ceftriaxone increases EAAT2 activity in rodent brains, which 
slowed the disease progression and thus prolonged survival in ALS mice 
(Cudkowicz et al., 2014; Lee et al., 2008). 
 
The trial was structured as a double-blind, placebo-controlled study. The 
first participant was recruited on September 4, 2006 for stage 1 and the first 
stage 3 participant entered on June 4, 2009. However, the trial was stopped early 
for futility by the independent Data Safety Monitoring Board (DSMB) on July 2012 
before all participants had 1 yr of treatment, as the last participant was recruited 
on December 14, 2011. For stages 1 (pharmacokinetics) and 2 (safety), 66 
participants were enrolled to determine cerebrospinal fluid and blood 
pharmacokinetics and safety of two dosages: 2 g/day and 4 g/day of ceftriaxone 
per central venous catheter (CVC). They were randomly assigned to either 
placebo, ceftriaxone 2 g, or ceftriaxone 4 g. Participants were adults (>18 yrs of 
age) with a diagnosis of possible, laboratory-supported probable, probable or 
definite ALS. They also had vital capacity greater than 60% of the normal 
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predicted for age and height as well as symptom duration less than 3 years 
before enrollment. Participants were permitted to use riluzole if they have been 
taking a stable dose for greater than or equal to 30 days. All participants of 
stages 1 and 2 continued on to stage 3 (efficacy) in blinded fashion. The 44 
participants previously assigned to 2 or 4 g ceftriaxone in stage 2 received 4 g 
and the 21 participants assigned to placebo continued to take placebo. 448 new 
participants were randomly assigned to 4 g/day ceftriaxone or placebo in a 2:1 
ratio. There was a total of 514 participants in stage 3: 341 on 4 g qd ceftriaxone 
and 173 on placebo. Stage 1 lasted for 7 days while stage 2 was for 20 weeks. 
At 20 weeks, the DSMB and two members of the steering committee used the 
information to select 4 g qd ceftriaxone dosage for stage 3. Participants receiving 
4 g qd ceftriaxone in stage 3 also received 300 mg bid ursodiol to manage 
hepatobiliary adverse events associated with ceftriaxone(Cudkowicz et al., 
2014). 
 
The co-primary endpoints were survival and change in function after 1 yr 
of treatment. Survival endpoint parameters included time to death, tracheostomy, 
or initiation of permanent assisted ventilation (PAV). Change in function was 
assessed using the slope of scores on the ALS Functional Rating Scale-Revised 
(ALSFRS-R). The secondary endpoints were changes from baseline in VC and 
changes in upper- and lower-limb muscle strength using hand-held dynamometry 
(HHD). Further examination included the ALS-Specific Quality of Life (ALSSQOL) 
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questionnaire to assess symptom severity, mood, intimacy, and social issues. To 
assess the quality of life of caregivers in regards to social, emotional, physical, 
time and developmental aspects of their relationships with the participants, the 
Caregiver Burden Inventory (CBI) was used (Cudkowicz et al., 2014). 
 
 
Figure 5. Log-Ranked Test for Survival Comparing Patients Receiving 4 g qd 
Ceftriaxone and Placebo. *Death, permanent assisted ventilation, tracheostomy 
(Cudkowicz et al., 2014). 
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Table 2. Summary of Results for Primary and Secondary Endpoints (Cudkowicz et 
al., 2014)* 
 
As stated above, this study was ended early due to futility, which was 
determined by the DSMD. There were no significant differences between the 
treatment groups in regards to survival, functional decline, or VC. For functional 
decline during stages 1 and 2, participants taking 4 g ceftriaxone had a 
nonsignificant slowing of functional decline of 0.51 units/month than those taking 
the placebo (p = 0.0416) (Table 2). During stage 3, there was no significant 
difference in functional decline after the interim (p = 0.196) or final analyses (p = 
0.237). Figure 5 demonstrates the log-ranked test for survival between patients 
receiving treatment and placebo. No significant differences after interim (p = 
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0.3680) or final analyses (p = 0.4146). Regarding VC, no significant differences 
between treatment groups noted during stages 1 and 2, or after interim or final 
analyses. HHD results also demonstrated no treatment effect on the percentage 
of baseline for upper or low extremities. No significant effects of treatment on the 
ALSSQOL and CBI as well (Cudkowicz et al., 2014). 
 
Ceftriaxone was also associated with a few serious adverse effects for 
pulmonary, gastrointestinal, hepatobiliary, and blood/bone marrow. Adverse 
event rates were significantly higher in the treatment group compared to the 
placebo group (Table 3). During stage 3 of the study, patients taking 4 g 
ceftriaxone plus ursodiol experienced significantly less adverse events compared 
to those taking 4 g ceftriaxone only (Table 4). 
 
Although ceftriaxone showed neuroprotective effects against glutaminergic 
excitotoxicity in preclinical studies, it failed to demonstrated clinical efficacy in this 
study. It was also difficult to keep the study completely blinded due to the 
adverse effects (Cudkowicz et al., 2014). 
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Table 3. Frequency of Adverse Events in Patients taking Ceftriaxone versus those 
taking Placebo (Cudkowicz et al., 2014). 
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Table 4. Frequency of Adverse Events in Patients taking Ceftriaxone versus those 
taking Ceftriaxone and Ursodiol (Cudkowicz et al., 2014) 
 
MEXILETINE 
Mexiletine is a cardiac antiarrhythmic agent and a use-dependent sodium 
channel blocker. This agent has been demonstrated to inhibit neuronal 
excitotoxicity and prevent human SOD1 motor neuronal cell death in vitro (Weiss 
et al., 2016). In a small open-label study in Machado-Joseph disease, a 
hereditary spinocerebellar neurodegenerative disorder that leads to degeneration 
of the anterior horn cells, mexiletine was shown to reduce muscle cramping 
(Kanai et al., 2003). Hyperexcitobility of the peripheral motor nerve axons have 
been shown to play a role in the generation of fasciculations and muscle cramps, 
which are bothersome symptoms of ALS (Weiss et al., 2016). 
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A phase II double-blind trial of sporadic ALS (sALS) was conducted to 
determine the safety and tolerability of mexiletine. 59 participants with sALS were 
randomized in a 1:1:1 ratio to placebo, 300 mg qd mexiletine, and 900 mg qd 
mexiletine for 12 weeks. The participants had to be on a stable dosage of riluzole 
and any other medications used for muscle cramps for ³60 days or have been off 
these medications for ³30 days prior to randomization. The primary endpoints of 
this phase II trial were safety and tolerability while the secondary endpoints were 
pharmacokinetic study from plasma and CSF, ALSFRS-R score, slow VC (SVC), 
and muscle cramp frequency and severity (Weiss et al., 2016). 
 
The study demonstrated that both 300 and 900 mg qd of Mexiletine were 
safe in sALS patients over a period of 12 weeks, however, only 300 mg qd was 
tolerable. Only 1 of 20 patients receiving 300 mg qd discontinued the treatment 
while 6 of 19 patients receiving 900 mg qd discontinued (p = 0.026). 1 patient 
taking the placebo discontinued due to death (Weiss et al., 2016). 
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Figure 6. Changes in mean ALSFRS-R and SVC from baseline (Weiss et al., 2016). 
 
Rates of decline of ALSFRS-R and SVC were not significantly different 
from the placebo (Figure 6). However, the study did show promising results in 
decreasing the frequency of muscle cramps and pain intensity (Figure 7). There 
was significant reduction in muscle cramp frequency with mexiletine treatment. 
The rate in the 300 mg qd treatment group was 31% of the placebo group (p = 
0.047); the rate in the 900 mg qd treatment group was 16% of the placebo group 
(p = 0.002). The intensity was 45% (p = 0.08) and 25% (0.005) of the placebo 
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group for the 300 and 900 mg qd treatment groups, respectively (Weiss et al., 
2016). 
 
 
Figure 7. Changes in mean muscle cramp frequency and pain intensity with 
mexiletine compared with placebo (Weiss et al., 2016) 
 
In another study, 60 participants with probable or definite ALS were 
randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg for 
a duration of 6 months. The ALSFRS-R scores and the strength-duration time 
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constant (SDTC), which is a measure of persistent sodium current, were 
recorded to study the efficacy and safety of mexiletine.  
 
The study did not demonstrate a significant difference between the two 
treatment groups in the ALSFRS-R total scores (p = 0.57). The SDTC also did 
not decrease with mexiletine. The riluzole only group had a lower SDTC than the 
mexiletine group (p = 0.049) (Figure 8) (Shibuya et al., 2015) 
 
In both studies, mexiletine failed to extend survival or slow the decline in 
ALS pathophysiology. No significant differences in ALSFRS-R, SVC, and SDTC 
were observed. In Shibuya et al, the study showed mexiletine could not suppress 
persistent sodium currents, therefore, could not determine a relationship between 
sodium currents and ALS progression (Shibuya et al., 2015). In Weiss et al, the 
study did demonstrate significant benefits of mexiletine in reducing the frequency 
and severity of muscle cramps in patients with ALS (Weiss et al., 2016). There is 
still a lot of uncertainty in the mechanism and interactions of mexiletine. Although 
current studies have not demonstrated a slowing of ALS progression, it remains 
a possible therapy for ALS patients and is worthy of further study (Shibuya et al., 
2015; Weiss et al., 2016). 
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Figure 8. ALSFRS-R Score and SDTC during 6 months (Shibuya et al., 2015) 
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DEXTROMETHORPHAN + Quinidine 
Dextromethorphan (DM) is a sigma-1 receptor agonist, which inhibit 
voltage gated-ion channels, potentiate ligand-gated channels, and exert a 
modest effect on serotonin uptake. Quinidine (Q) inhibits cytochrome P450 
isoenzyme CYP2D6 and, therefore, protects DM from O-demethylation. As a 
sigma-1 agonist, DMQ was hypothesized to palliate speech, swallowing, and 
pseudobulbar affect (PBA). Sigma-1 receptors were found to be localized to the 
brainstem and cerebellum, which are involved in the regulation of emotional 
expression (Smith et al., 2017). 
 
A study by Brooks et al. tested the effects of the combination of DM and Q 
(AVP-923) on the pseudobulbar affect in ALS. AVP-923 consisted of 30 mg DM 
and 30 mg Q. The study was structured as a randomized, double-blind trial that 
tested AVP-923 to its components. The treatment was given bid for 28 days with 
evaluations on days 1, 15, and 29. The primary efficacy endpoint was the change 
from baseline in the Center for Neurologic Study Lability Scale (CNS-LS) score; 
the secondary endpoint were laughing/crying episode rates and changes in 
Visual Analog Scales for Quality of Life (QOL) and Relationship (QOR). There 
were 65 patients for the AVP-923 group, 30 for DM, and 34 for Q (Brooks et al., 
2004).  
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At the end of the study, results demonstrated AVP-923 patients 
experienced 3.3-points greater improvements in CNS-LS than DM patients (p = 
0.001) and 3.7-points greater improvements than Q patients (p < 0.001). AVP-
923 treatment also resulted in lower laughing/crying episode rates and improved 
QOL and QOR scores (p < 0.01 for all endpoints). This study showed AVP-923 
palliates PBA in ALS (Brooks et al., 2004). 
 
DMQ was shown to also reduce PBA in patients with multiple sclerosis 
(MS), further solidifying the results shown in Brooks et al. The study with 150 MS 
patients was over a 12-week period that compared DMQ against a placebo. The 
CNS-LS scores were significantly reduced in the DMQ treatment group 
compared to the placebo group (p < 0.0001) at all clinic visits (days 15, 29, 57, 
and 85) (Figure 9). The number of crying or laughing episodes (p £ 0.0077), QOL 
(p < 0.0001), QOR (p = 0.0001), and pain intensity score (p = 0.0271) all favored 
the DMQ treatment group (Panitch et al., 2006). 
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Figure 9. Adjusted mean CNS-LS comparing AVP-923 and placebo treatment 
groups (Panitch et al., 2006) 
 
Following these studies, a drug called Nuedexta (20 mg 
dextromethorphan + 10 mg quinidine) was approved by the U.S. FDA in 2011 for 
the treatment of PBA secondary to ALS. A recent study with Nuedexta 
hypothesized that Nuedexta could palliate speech and swallowing given it 
reduced PBA. A phase II, double-blind trial evaluated the effect of Nuedexta 
treatment on bulbar functions, which include speech, swallowing, and salivation, 
in ALS patients. 60 patients with a diagnosis of probable or definite ALS were 
recruited. The patients had a disease duration of less than two years from the 
time of diagnosis and bulbar dysfunction manifested by dysphagia and/or 
dysarthria. If the patients were taking riluzole, they had to have been on the drug 
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for at least 30 days prior to the study. The study excluded any patients who have 
prior use of DMQ, DM, or Q or a sensitivity to these drugs. The patients were 
randomly assigned in a 1:1 ratio to either DMQ or placebo treatment groups. The 
primary efficacy endpoint was a self-report via the Center for Neurologic Study 
Bulbar Function Scale (CNS-BFS) (Table 5). The secondary efficacy endpoint 
was rater-administered ALSFRS-R (Smith et al., 2017). 
 
The CNS-BFS is a self-report scale that evaluates three domains for the 
bulbar function: speech, swallowing, and salivation. Thus, the objective of the 
study to determine whether DMQ is able to exert a palliative effect on speech, 
swallowing, and salivation can be determined by a significant change in the CNS-
BFS score. The validity of the CNS-BFS, which was modeled after the CNS-LS, 
was tested in a large ALS patient population (n = 122) recruited online via a 
social networking site and again in 120 patients consisting of the 60 patients in 
the main study and an additional 60 ALS patients. For validation, the reported 
CNS-BFS score was compared to a self-report and report by a clinician regarding 
their speech, swallowing, and ability to handle oral secretions. The score was 
well correlated with the clinician assessments (statistically significant) (Smith et 
al., 2017).  
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Table 5. Center for Neurologic Study Bulbar Function Scale (CNS-BFS) (Smith et 
al., 2017)* 
 
The study design included 2 treatment groups: placebo and Nuedexta. 
Patients were randomly designated to their treatment groups for 28 to 30 days, 
followed by a 10 to 15 day washout period, then switched to the opposite 
treatment group for the remaining period of the 70 day trial (Figure 10) (Smith et 
al., 2017). 
 
 
	33 
 
Figure 10. Study Design (Smith et al., 2017) 
 
Overall, the study demonstrated that DMQ could improve speech and 
swallowing. The mean CNS-BFS score of the treatment group (53.5) was 
significantly lower than the score of the placebo group (59.3) (p < 0.001). 
Additionally, each domain of bulbar function in the CNS-BFS improved with DMQ 
treatment. For salivation, the score was 15.8 with placebo and 14.4 with 
treatment (p = 0.004). For speech, the score was 24.6 with placebo and 22.2 with 
treatment (p = 0.003). Lastly for swallowing, the score was 18.9 with placebo and 
17.1 with treatment (p = 0.009). Although it was uncertain if DMQ treatment 
would have a palliative effect on impaired speech and swallowing in patients 
without PBA, the study showed that patients with and without PBA experienced a 
similar improvement in the their total CNS-BFS scores following treatment (Smith 
et al., 2017).  
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As shown in prior studies, Nuedexta reduced inappropriate emotionality as 
determined by the CNS-LS. The CNS-LS scores were 13.7 for placebo and 10.7 
for Nuedexta (p < 0.001). In the rater-administered ALSFRS-R, there was 
significant improvement in the bulbar component with Nuedexta treatment (p = 
0.003). However, the motor, respiratory, or swallowing components of the survey 
were not significantly affected (Smith et al., 2017). 
 
In the quantitative measures for speech and swallowing of the study, DMQ 
treatment resulted in improvements without statistical significance. The number 
of words read per minute increased from 103 in the placebo period to 107 in the 
treatment period (p = 0.15). The time it took to swallow 30 mL of water decreased 
from 13.1 s to 12.2 s. The time it took to swallow a teaspoon of cereal also 
decreased from 19.5 s to 18.5 s (Smith et al., 2017).  
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Figure 11. Comparison of effects of Nuedexta and placebo treatment on 
changes in the Center for Neurologic Study Bulbar Function Scale (CNS-BFS). (A) 
Mean CNS-BFS scores for each treatment arm throughout the course of the 
clinical trial. Measurements were obtained at baseline, and during 3 subsequent 
clinical visits. (B) Histogram of unadjusted treatment-dependent change in CNS-
BFS total scores among patients who completed the study. Negative values 
indicate larger reductions in CNS-BFS total scores after receiving DMQ. Positive 
values indicate larger reductions after receiving placebo. (C) Interaction plot of 
CNS-BFS versus PBA status. Demonstrates the improvement in bulbar function 
(CBS-BFS) associated with DMQ treatment regardless of the presence or absence 
of PBA at baseline (Smith et al., 2017). 
 
RETIGABINE 
Retigabine is a Kv7 potassium channel activator, which has been shown 
to block hyperexcitability and improve motor neuron survival in vitro. Previous 
studies demonstrated that retigabine blocks hyperexcitability across a wide range 
of fALS patients harboring additional SOD1 mutations, C9orf72 repeat 
expansions, and FUS mutations (Kovalchuk et al., 2018; Wainger et al., 2014). 
 
A study by Wainger et al. in 2014 used induced pluripotent stem cells 
(iPSC) to model fALS patient motor neurons harboring an aggressive SOD1 
mutation. iPSC technology enables neurons of specific subtypes of diseases to 
be derived from disease patients and control subjects. This thereby provides an 
in vitro platform for discovering human neuron phenotypes that could reflect the 
individual disease. The study used iPSC derived motor neurons from two control 
subjects and two unrelated fALS patients who harbored the same aggressive 
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SOD1 mutations. After confirming the iPSC derived motor neurons of the fALS 
patients were hyperexcitable, they tested whether retigabine would reduce 
excitability compared to the control-derived motor neurons (Wainger et al., 2014). 
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Figure 12. Retigabine Reduces Motor Neuron Excitability and Increases 
Survival. (A) Rheobase measurements in an ALS-derived motor neuron in a whole-
cell patch clamp before (left) and after (right) the application of 10 uM retigabine (p 
= 0.05). (B) Current clamp recording showing the effect of 10 uM retigabine on 
membrane voltage and spontaneous firing. (C) Dose response curve for retigabine 
on suppression of spontaneous action potentials. (D) Effect of vehicle (open 
circles) and 1 uM retigabine (filled circles) treatment from days 14 – 28 of cultures 
on the survival of the motor neurons measured at day 30 (Wainger et al., 2014).  
 
As shown in Figure 12, the tests demonstrated that retigabine did in fact 
reduce excitability in ALS-derived motor neurons. There was significant reduction 
in ALS-derived motor neurons after applications of 10 uM retigabine (p = 0.05) 
(Figure 12A). This study demonstrated that ALS patient-derived motor neurons 
have reduced delayed-rectifier potassium current amplitudes compared to 
control-derived motor neurons. This may be the deficit that underlies their 
hyperexcitability (Wainger et al., 2014). 
 
A phase II pharmacodynamic trial evaluating the effect of retigabine has 
recently completed their trial. However, the results are yet to be available. They 
randomly allocated subjects to either 600 mg qd, 900 mg qd, or placebo for 
approximately 10 weeks. The primary outcome measurement was a change in 
short-interval intracortical inhibition (SICI) measured by transcranial magnetic 
stimulation (TMS). The various secondary outcome measurements were also 
measured by TMS as well as threshold tracking axonal nerve conduction studies 
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(“Clinical Trial of Ezogabine (Retigabine) in ALS Subjects - Full Text View - 
ClinicalTrials.gov,” n.d.). 
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DISCUSSION 
 
Amyotrophic lateral sclerosis is a paralyzing neurodegenerative disease, 
which has efficiently evaded our research. Research has shown there are three 
major hypothesized pathophysiologic mechanisms for ALS, which include 
excitotoxicity, protein aggregation, and oxidative stress. Currently, only two drugs 
are approved by the FDA for the treatment of ALS: riluzole and edaravone. 
Riluzole targets the excitotoxicity pathway while edaravone targets the oxidative 
stress pathway. These drugs are not a cure, but they show modest effects in 
prolonging survival. This review focused on treatments targeting the excitotoxicity 
pathway of ALS. 
 
Since riluzole was approved by the FDA in 1995, numerous possible 
treatment modalities tackling the excitotoxicity pathway of ALS were studied. 
However, no novel drug demonstrated significant prolonging of survival or 
improvement in symptoms. The major drugs that were studied were gabapentin, 
cefriazone, mexiletine, dextromethorphan with quinidine, and retigabine. All five 
drugs had positive results in vitro and animal models, however, this did not 
translate to clinical phase III trials.  
 
Gabapentin revealed a neuroprotective effect in tissue culture models of 
glutamate excitotoxicity and extended survival in mSOD1 mice. However, when 
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tested for slowing the rate of decline in muscle strength of ALS patients, 
gabapentin failed to show significant differences from placebo. 
 
Ceftriaxone also showed optimistic results in vitro, significantly increasing 
EAAT2 activity and GLT-1 expression in rodent brains, which would increase 
synaptic glutamate reuptake. Theoretically, this would slow disease progression 
and thus prolong survival. Clinical trials would prove this theory wrong. Studies 
testing survival revealed no significant effects on treatment on survival or ALS 
symptoms. 
 
Both gabapentin and ceftriaxone targeted reducing excitotoxicity by 
reducing the excess amount of glutamate in the synapse. They promoted the 
reuptake of the glutamate. Although the drugs were effective in vitro and in 
animal models, the hypothesis disappointingly did not improve survival or 
alleviate ALS symptoms.  
 
Unlike gabapentin or ceftriaxone, mexiletine reduced the overactivity of 
sodium channels to inhibit the excessive release of glutamate, which causes 
excitotoxicity. In vitro studies with human SOD1 motor neurons demonstrated 
mexiletine to inhibit neuronal excitotoxicity and prevent cell death. Multiple 
clinical trials with mexiletine failed to show evidence of prolonging survival or 
slowing ALS pathophysiology. Unfortunately, a relationship between sodium 
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currents and ALS progression could not be determined. Mexiletine did, however, 
reduce the frequency and severity of muscle cramps in ALS patients. Mexiletine 
may not have slowed ALS progression, but it remains a possible therapy for ALS 
patients. 
 
Dextromethorphan in combination with quinidine, or AVP-923, targeted the 
counterpart of mexiletine. Dextromethorphan stimulated the activity of potassium 
channels, which are underactive in ALS patients. Quinidine stabilizes 
Dextromethorphan and increases its half-life. Although AVP-923 did not prolong 
survival, it significantly improved speech and swallowing and reduced PBA affect 
in ALS patients. This study with AVP-923 emphasized the importance of 
palliative care in improving quality of life and quality of relationships and the 
possibility of deeper understanding of the ALS pathophysiology by studying 
palliative care treatment modalities.  
 
Continual research is being conducted to obtain a greater understanding 
and to formulate possible treatment modalities, such as retigabine, for ALS. 
These past studies shine a light in successes and failures, which could provide 
guidance to future studies. 
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